Promising Results of Zidesamtinib in Treating ROS1-Positive NSCLC Patients Post-TKI Therapy
Zidesamtinib shows promising durable responses in ROS1-positive NSCLC patients, including those with brain metastases and prior TKI treatment, demonstrating potential as a targeted therapy option.
Zidesamtinib, an innovative next-generation ROS1 tyrosine kinase inhibitor (TKI), has demonstrated significant clinical activity and sustained responses in patients with ROS1-positive non-small cell lung cancer (NSCLC) who previously undergone TKI treatment. This highly selective, brain-penetrant, and TRK-sparing agent was evaluated in the Phase I/II ARROS-1 trial, with results presented at the 2025 World Conference on Lung Cancer by Dr. Alexander Edward Drilon from Memorial Sloan Kettering Cancer Center.
The trial enrolled patients with advanced or metastatic ROS1+ NSCLC, with a focus on those who had received prior TKI therapies. The pivotal analysis included 117 efficacy-evaluable patients who started on a daily dose of 100 mg zidesamtinib before May 31, 2024. Additionally, preliminary data from 35 TKI-naive patients showed remarkable outcomes.
Among the TKI pre-treated group, which had a median of two prior therapies—including multiple ROS1 TKIs like lorlatinib, repotrectinib, and taletrectinib—durable responses were observed, even in patients with brain metastases or ROS1 mutations like G2032R. The objective response rate was 44%, and at 12 months, 78% of responders maintained response. Notably, patients with prior crizotinib or entrectinib alone exhibited an ORR of 51%, with a 12-month DOR rate of 93%.
In the TKI-naive cohort, the results were particularly encouraging with an ORR of 89% and a 96% DOR rate at 12 months. Intracranial activity was notable, with an intracranial ORR of 83%, including complete responses, and no CNS progression observed at data cutoff.
The treatment was generally well tolerated; common adverse events included peripheral edema, constipation, elevated CPK, fatigue, and dyspnea, with most being manageable and severe cases being rare. Dose reductions were needed in 10% of patients, and only 2% discontinued treatment due to side effects.
Dr. Drilon emphasized that zidesamtinib’s design allows for significant disease control in patients with few options left, especially given its brain-penetrance and selectivity. The positive findings in both pre-treated and treatment-naive populations advocate for further development of this promising agent.
Source: https://medicalxpress.com/news/2025-09-zidesamtinib-durable-responses-ros1-tki.html
Stay Updated with Mia's Feed
Get the latest health & wellness insights delivered straight to your inbox.
Related Articles
Assessing the Accuracy of Racial Minority Representation in US Cancer Registries
This article explores how well US cancer registration systems capture racial minority data and the implications for addressing health disparities. Recent studies highlight improvements and ongoing challenges in accurately classifying multiracial populations to better understand cancer incidence and mortality rates.
Higher Rates of Leg Amputation Due to Arterial Disease in Disadvantaged Communities
A new study reveals that leg amputations caused by arterial disease are four times more common in disadvantaged communities in England, highlighting significant health inequalities and the urgent need for targeted prevention efforts.
Large-scale Study Finds No Significant Increase in Cancer Risk with JAK Inhibitors for Rheumatoid Arthritis Patients
A large international study shows no significant overall increase in cancer risk for rheumatoid arthritis patients treated with JAK inhibitors, supporting their continued use under careful monitoring.
Progressive Decline in Daily Walking Patterns Among COPD Patients Study Reveals
A recent study reveals that walking patterns deteriorate in COPD patients as the disease advances, highlighting the importance of digital gait analysis for early intervention and improved patient care.